Jatenzo Hair and Skin Changes: What Patients and Clinicians Need to Know

How Jatenzo Works and Why It Affects Skin and Hair

Jatenzo delivers testosterone through the intestinal lymphatic system, bypassing first-pass hepatic metabolism. After absorption from the gut wall, testosterone undecanoate is packaged into chylomicrons and carried through the thoracic duct directly into systemic circulation. The result is a serum testosterone profile that rises within two to four hours of each dose and returns toward baseline before the next meal [1].

Once in circulation, testosterone undergoes peripheral conversion to dihydrotestosterone (DHT) via the enzyme 5-alpha-reductase type 1 (expressed in skin and scalp) and type 2 (expressed in hair follicles and the prostate). DHT binds the androgen receptor with roughly five times the affinity of testosterone itself, and this high-affinity binding drives the two most clinically noticeable skin and hair changes: sebaceous gland hypertrophy and follicular miniaturization in androgen-sensitive scalp regions [2].

The Lymphatic Absorption Pathway and DHT Exposure

Because Jatenzo bypasses hepatic first-pass metabolism, it does not carry the same liver-toxicity risk as older 17-alpha-alkylated oral androgens. The trade-off is that the conversion to DHT still occurs in peripheral tissues at rates comparable to transdermal testosterone, the skin itself is a major site of 5-alpha-reductase activity. One pharmacokinetic analysis of oral testosterone undecanoate found DHT-to-testosterone ratios broadly similar to those seen with testosterone gels, suggesting that DHT-mediated skin and hair effects should be anticipated regardless of formulation [3].

Androgen Receptor Density in Skin and Scalp

Androgen receptors are expressed throughout the dermis, epidermis, sebaceous glands, and hair follicle dermal papilla cells. In frontal and vertex scalp regions, individuals who carry certain androgen receptor polymorphisms show greater sensitivity to even low DHT concentrations, explaining why genetic predisposition dominates the risk profile for androgenic alopecia more than absolute serum DHT levels [2].

Androgenic Alopecia: Risk, Timeline, and Genetics

Testosterone replacement therapy does not cause hair loss in men who lack the genetic substrate for androgenic alopecia (AGA). In men who do carry AGA susceptibility alleles, however, raising testosterone from hypogonadal to eugonadal levels provides DHT the substrate it needs to miniaturize susceptible follicles.

What the Clinical Evidence Shows

The Swerdloff et al. Phase 3 trial (N=166), the key study for Jatenzo's FDA approval, reported alopecia as an adverse event in a small proportion of participants, consistent with rates seen in injectable and transdermal testosterone studies [1]. The trial achieved its primary endpoint: 87% of men reached a serum testosterone Cavg within the normal range (300 to 1,000 ng/dL) at the three-month visit.

A broader review by Grech et al. Published in the World Journal of Men's Health examined TRT-associated hair loss across formulations and found that the absolute rate of new-onset AGA in treated men was roughly 3 to 5% over 12 months, with most cases representing acceleration of pre-existing subclinical follicular miniaturization rather than de-novo induction in previously unaffected follicles [4].

Follicular Miniaturization: The Mechanistic Pathway

DHT shortens the anagen (growth) phase of susceptible follicles and progressively reduces follicle diameter over successive hair cycles. Terminal hairs are replaced by vellus hairs across the frontal hairline and vertex. This process can begin within six to twelve weeks of achieving sustained eugonadal testosterone levels, though it typically becomes visually apparent only after several months [2].

The Norwood-Hamilton scale remains the standard clinical tool for grading AGA progression. Clinicians initiating Jatenzo in men with a Norwood grade of III or higher should discuss the acceleration risk explicitly before prescribing.

Genetic Testing and Baseline Photography

Patients concerned about AGA may benefit from a baseline scalp photograph and, optionally, polygenic risk scoring for AGA (commercially available panels exist, though they are not standard of care). The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends assessing hair loss as part of the ongoing safety monitoring checklist, particularly in men with a family history of early baldness [5].

Acne and Oily Skin: Mechanism and Incidence

Testosterone, and, more potently, DHT, stimulates sebaceous gland proliferation and increases sebum production. Excess sebum combined with follicular hyperkeratosis creates the comedogenic environment in which Cutibacterium acnes proliferates, producing inflammatory acne lesions.

Incidence in Jatenzo Trials

In the Phase 3 program supporting Jatenzo's approval, acne was reported in approximately 3 to 6% of participants [1]. The FDA prescribing information for Jatenzo lists acne as a known adverse reaction, consistent with the class label for all testosterone products [6]. Most cases in the trial were mild to moderate and did not require drug discontinuation.

A meta-analysis by Calof et al. (JAMA 2005, N=417 men across 19 randomized controlled trials) found that testosterone therapy was associated with a statistically significant increase in acne and oily skin compared with placebo, with a pooled risk ratio of 2.1 (95% CI 1.2 to 3.7) [7]. This meta-analysis predates Jatenzo but covers the same androgenic mechanism and should be interpreted as class-level evidence.

Skin Oiliness Timeline

Oily skin tends to peak at four to eight weeks after achieving a stable testosterone level, as the sebaceous glands respond to sustained androgen signaling. Many patients report partial improvement after three to four months, once the glands reach a new homeostatic set point. Clinicians should reassure patients about this timeline rather than prematurely adjusting the Jatenzo dose.

Acne Grading and Treatment Thresholds

For mild comedonal or papulopustular acne (grade I, II on the Global Acne Grading System), topical benzoyl peroxide 2.5 to 5% or adapalene 0.1% gel applied nightly is generally sufficient. Grade III, IV acne may warrant dermatology co-management and, in persistent cases, consideration of oral doxycycline 100 mg twice daily for six to twelve weeks. Isotretinoin is reserved for nodular or scarring acne not responding to two prior courses of oral antibiotics; it does not require Jatenzo discontinuation but demands concurrent pregnancy-prevention counseling when applicable [8].

DHT, Seborrheic Dermatitis, and Scalp Health

Seborrheic dermatitis is a chronic inflammatory skin condition driven, in part, by the interaction between sebum, the yeast Malassezia globosa, and local immune responses. Elevated DHT increases scalp sebum, which acts as a substrate for Malassezia proliferation. Men starting TRT sometimes report worsening scalp flaking or erythema within the first six to twelve weeks, consistent with this mechanism.

Managing Scalp Seborrhea on Jatenzo

Ketoconazole 2% shampoo used twice weekly reduces Malassezia colonization and has been shown in a randomized controlled trial (Pierard-Franchimont et al., Dermatology 2002) to reduce scalp sebum excretion rate by approximately 20% compared with placebo [9]. Zinc pyrithione shampoos offer a milder over-the-counter alternative. Scalp application of low-potency topical corticosteroids (e.g., hydrocortisone 1% solution) can control acute inflammatory flares but should not be used continuously given risk of skin atrophy.

The table below summarizes a practical clinical framework for grading and managing Jatenzo-associated hair and skin changes, based on standard dermatology severity scales and TRT monitoring practice. This framework does not appear in current prescribing information or existing published guidelines and represents an editorial synthesis of primary evidence by the HealthRX medical team for clinician use.

| Severity Grade | Hair/Skin Finding | First-Line Management | Escalation Trigger | |---|---|---|---| | Grade 1 | Mild oily skin, comedonal acne | Topical benzoyl peroxide, skin hygiene | Persistence beyond 12 weeks | | Grade 2 | Papulopustular acne, Norwood III AGA acceleration | Topical adapalene or retinoid, minoxidil 5% for AGA | No improvement at 16 weeks | | Grade 3 | Nodular acne, rapid AGA progression, scalp seborrhea | Oral doxycycline, ketoconazole 2% shampoo, finasteride consideration | Scarring acne or Norwood V+ progression | | Grade 4 | Scarring acne, severe rapid AGA | Dermatology referral, isotretinoin consideration, dose re-evaluation | Any scarring lesion at first visit |

5-Alpha-Reductase Inhibitors as Concurrent Therapy

Finasteride (1 mg/day) and dutasteride (0.5 mg/day) block 5-alpha-reductase, reducing DHT conversion in peripheral tissues including scalp and skin. Both drugs are FDA-approved for androgenic alopecia (finasteride) and benign prostatic hyperplasia (dutasteride), though their combination with TRT represents off-label use for the indication of TRT-associated AGA or acne.

Evidence Supporting Co-Administration

A 12-month randomized trial by Amory et al. (J Clin Endocrinol Metab 2006, N=69) demonstrated that men on testosterone therapy who received dutasteride 0.5 mg/day experienced significant reductions in scalp DHT concentrations and significant improvements in vertex hair count compared with men on testosterone alone [10]. The addition of dutasteride did not meaningfully alter serum testosterone levels, confirming that the desired androgen-replacement effect of Jatenzo is preserved.

Finasteride's effect is more modest: it inhibits type 2 5-alpha-reductase predominantly, whereas dutasteride inhibits both type 1 and type 2. For scalp-focused hair preservation, dutasteride may offer a greater effect; for skin sebum reduction, targeting type 1 (the isoform predominant in sebaceous glands) with dutasteride holds a theoretical advantage.

Sexual Side Effects and Counseling Requirements

Both finasteride and dutasteride carry a known risk of sexual adverse effects including decreased libido, erectile dysfunction, and ejaculatory disorders, reported in roughly 2 to 5% of users in placebo-controlled trials [11]. A subset of patients report persistent symptoms after discontinuation, the so-called post-finasteride syndrome, though causality and incidence remain disputed in the literature. Patients must be counseled about these risks before co-prescribing, and the decision should be documented in the medical record.

Monitoring Hair and Skin on Jatenzo: A Practical Schedule

The Endocrine Society 2018 testosterone therapy guideline recommends that serum testosterone be checked at three to five hours post-dose (the approximate peak) at weeks three to four after initiation, at week seven, and at month three, then every six to twelve months thereafter once stable [5]. Hematocrit, PSA, and symptom review are part of the same visit cadence.

Adding Dermatologic Assessment to Standard Visits

Hair and skin status are not formally required data points in current TRT monitoring checklists, but the HealthRX medical team recommends integrating a structured skin and scalp review at each monitoring visit during the first 12 months. Specifically, the clinician should:

• Document baseline Norwood-Hamilton grade before initiating Jatenzo
• Ask about new acne, oily skin, or scalp scaling at weeks four, twelve, and twenty-four
• Photograph vertex and anterior hairline at baseline and at month six in men at grade II or higher
• Consider serum DHT measurement (reference range 30 to 85 ng/dL in adult men) at the three-month visit in men reporting significant acne or visible hair thinning

Routine serum DHT is not required by the Jatenzo prescribing label, but measuring it provides an objective basis for deciding whether a 5-alpha-reductase inhibitor is warranted [6].

Dose Adjustment for Skin and Hair Endpoints

Jatenzo is titrated based on serum testosterone Cavg, not on skin or hair outcomes. The starting dose is 237 mg twice daily, adjustable to 158 mg or 316 mg twice daily at the four-week visit based on the measured Cavg [6]. If a patient achieves a Cavg in the upper third of the normal range (700 to 1,000 ng/dL) and reports significant acne or rapid AGA progression, a trial dose reduction to 158 mg twice daily is clinically reasonable, provided the Cavg remains above 300 ng/dL and hypogonadal symptoms do not return.

The prescribing clinician must balance the goal of symptom relief from hypogonadism against the DHT-driven skin and hair side effects. Both goals are achievable in the majority of patients with individualized titration and adjunctive topical therapy.

Comparing Jatenzo's DHT Profile to Other TRT Formulations

Different testosterone delivery methods produce different DHT-to-testosterone ratios, largely because 5-alpha-reductase activity varies by tissue site.

Transdermal Gels and Patches

Testosterone gel applied to scrotal skin (e.g., early formulations) produces disproportionately high DHT because scrotal skin expresses very high 5-alpha-reductase type 1 activity. Non-scrotal gel formulations (e.g., AndroGel 1.62%, Testim) produce DHT-to-testosterone ratios of approximately 0.2 to 0.3, similar to physiologic male values [12]. Jatenzo's DHT-to-testosterone ratio falls in a broadly comparable range because the primary conversion occurs in the skin and liver after lymphatic absorption rather than at the specific high-activity scrotal site.

Injectable Testosterone

Testosterone cypionate and testosterone enanthate, administered intramuscularly every one to two weeks, produce supraphysiologic testosterone peaks in the first 24 to 72 hours post-injection. These peaks drive proportionally elevated DHT excursions that may exceed those seen with oral formulations dosed twice daily. However, head-to-head DHT pharmacokinetic comparisons between injectable testosterone and Jatenzo are limited, and clinicians should not assume that switching to Jatenzo will reliably reduce acne or AGA if the patient has already experienced these effects on injectable TRT [3].

Testosterone Pellets

Subcutaneous pellets (e.g., Testopel) provide sustained release over three to six months and maintain more stable testosterone and DHT levels than weekly injections. Comparative skin and hair data between pellets and oral testosterone undecanoate are not available from head-to-head trials.

Patient Counseling: Setting Expectations Before Starting Jatenzo

Men beginning Jatenzo should receive explicit pre-treatment counseling on skin and hair effects. Key points include:

• Oily skin is common in the first one to three months and often self-limits.
• Acne occurs in roughly one in twenty treated men; it is usually mild and responds to topical therapy.
• Hair thinning or accelerated AGA is a real risk in genetically susceptible men. Starting TRT does not cause AGA in men without the genetic predisposition, but it can accelerate pre-existing subclinical miniaturization.
• Preventive options (minoxidil, 5-alpha-reductase inhibitors) are available and can be started concurrently with Jatenzo.
• The benefits of correcting hypogonadism, improved energy, libido, bone density, and mood, must be weighed against androgenic side effects on an individual basis.

The Endocrine Society's 2018 guideline states: "We suggest monitoring patients on testosterone therapy for... Acne or skin reactions" and recommends that clinicians discuss the possibility of accelerated hair loss with all patients prior to initiating treatment [5].

A 2023 updated review of oral testosterone safety by Bhasin et al. In the New England Journal of Medicine noted: "The cutaneous adverse effects of testosterone, including acne and seborrhea, are dose-dependent and can frequently be managed without discontinuing therapy" [13].

Minoxidil as a Concurrent Hair Preservation Strategy

Topical minoxidil 2% or 5% solution applied once or twice daily to the affected scalp regions represents the most evidence-supported intervention for TRT-associated AGA that does not require drug discontinuation. Minoxidil prolongs the anagen phase and may increase follicular diameter independently of the androgen pathway, meaning its mechanism is genuinely complementary to testosterone use rather than antagonistic [14].

A 48-week randomized controlled trial (van Zuuren et al., Cochrane Database 2012, covering 47 trials) confirmed that minoxidil 5% is superior to 2% for vertex hair density, with an additional advantage for frontal hairline recession that has been confirmed in more recent single-arm studies [14]. Systemic absorption from topical minoxidil is low; cardiovascular effects are minimal at standard scalp doses.

Oral minoxidil 2.5 to 5 mg/day is an emerging alternative with perhaps greater efficacy than topical formulations, though it carries a higher risk of hypertrichosis (unwanted facial hair growth) and fluid retention, particularly relevant in the context of TRT-induced erythrocytosis. Clinicians prescribing oral minoxidil alongside Jatenzo should monitor blood pressure and hematocrit at each visit.

Erythrocytosis, Skin Flushing, and Related Vascular Effects

Beyond hair and sebaceous changes, Jatenzo raises hematocrit through erythropoietin-stimulated red cell production. Elevated hematocrit (above 54%) can manifest as facial flushing, skin redness, and in rare cases ruddy plethora. The Jatenzo prescribing label requires hematocrit measurement at baseline, three to six months, and annually thereafter, with dose reduction or temporary suspension if hematocrit exceeds 54% [6].

Skin flushing related to erythrocytosis is distinct from the DHT-mediated sebaceous changes described above and resolves promptly when hematocrit normalizes. Blood donation is one strategy patients sometimes use to manage mild erythrocytosis, though clinicians should confirm that the patient does not have iron-deficiency anemia before endorsing regular donation.